English(EN) Mainland China funds increase stakes in Hong Kong biotech amid surge of licensing deals

中国基金在行业反弹之际增持香港生物科技投资

作者 PulseAugur 编辑部 · [1 个来源] · 2026-07-16 03:03

中国内地投资基金正增持在香港上市的生物科技公司股份，分析人士称其估值吸引且股价相对较低。易方达基金和富国基金等公司近期增持了基因编辑公司百图生物的股份，该公司股价已大幅上涨。包括信达生物和众生药业在内的更广泛的恒生创新药物指数也出现了显著上涨，表明生物科技行业趋势向好。 AI

影响生物科技投资增加可能会加速人工智能在药物发现和开发中的整合。

排序理由主要基金在特定行业（生物科技）的重大投资活动。[lever_c_demoted from significant: ic=1 ai=0.4]

AI 生成摘要 · Google Gemini · 来自 1 个来源。我们如何撰写摘要 →

本文如何被排名

Signal score: 0 / 100; Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket: Research; 主要基金在特定行业（生物科技）的重大投资活动。[lever_c_demoted from significant: ic=1 ai=0.4]
Source corroboration: Single-source cluster; Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics: funding, product; Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance: Standard; On-topic for AI-industry coverage; kept in the public index.
Story freshness: 46 days old; Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

完整方法见我们的编辑标准。

SCMP — Tech TIER_1 English(EN) · Julie Zhang · 2026-07-16 03:03

中国内地基金增持香港生物科技股份，因授权交易激增

A growing number of mainland Chinese institutional fund managers have built up stakes in Hong Kong-listed biotechnology stocks over the past month, drawn by attractive valuations amid a surge in cross-border licensing deals in the sector. China’s largest mutual fund manager, E Fu…